SEHA Launches CyberKnife Technology At Tawam Hospital To Enhance Cancer Treatment Options

PureHealth has introduced CyberKnife technology at Tawam Hospital, part of the SEHA network, marking its debut in Abu Dhabi. This advancement strengthens the emirate's reputation as a leading healthcare hub. The CyberKnife S7 system, now available at Tawam Hospital, is the most advanced in the UAE. It offers non-invasive radiotherapy solutions that improve cancer care by using precise robotic systems to enhance patient outcomes and quality of life.

The CyberKnife system delivers high-dose radiation with pinpoint accuracy to cancer cells, eliminating the need for surgery. This method is particularly beneficial for tumours in sensitive areas where traditional surgery poses risks. Since its introduction, 23 patients have been treated at Tawam Hospital, including cases of prostate cancer and brain tumours. This technology allows precise targeting while preserving healthy tissues.

Dr. Noura Khamis Al Ghaithi, Under-Secretary of the Department of Health – Abu Dhabi, stated, "Guided by our vision of providing world-class healthcare, Abu Dhabi continues to adopt and implement the latest technologies to improve the health and well-being of our community and reinforce the emirate’s position as a leading global healthcare destination. Robotic technologies and modern medical innovations, such as those now available at Tawam Hospital, are transforming care systems, harnessing the power of science and innovation to save and enhance lives."

Rashed Al Qubaisi, Group Chief Operating Officer of PureHealth, highlighted their dedication to advancing healthcare: "The launch of CyberKnife is a powerful example of PureHealth’s commitment to redefining the future of healthcare. This is more than a treatment innovation - it reflects our ambition to build a future-ready health system rooted in precision, innovation, and global excellence. By embedding advanced solutions like CyberKnife into national care pathways, we are not only enhancing outcomes at scale but also reinforcing the UAE’s position as a global pioneer in next-generation healthcare."

Saeed Jaber Al Kuwaiti, Group CEO of SEHA, emphasised their focus on patient-centric care: "This milestone reflects our unwavering commitment to delivering personalised, high-precision care that puts the patient first. By integrating advanced technologies like CyberKnife, we are improving outcomes, minimising treatment burdens, and enhancing the overall care experience. It is a clear step forward in our mission to continuously raise the standard of care and ensure every patient benefits from the most effective, evidence-based treatments available."

Expanding Treatment Options

The CyberKnife technology treats various tumours including brain and spinal tumours and cancers affecting organs like lungs and liver. It also addresses complex head and neck cancers along with non-cancerous conditions such as trigeminal neuralgia. The introduction of this technology not only enhances SEHA's capabilities but also demonstrates its commitment to medical innovation by attracting top oncology talent.

This development signifies a shift towards offering non-invasive treatments that are more effective for cancer patients in Abu Dhabi. With its ability to treat both benign and malignant tumours without surgical incisions or complex procedures, CyberKnife represents a significant advancement in regional cancer care.

With inputs from WAM